amifostine

S-2-(3-aminopropylamino)ethylphosphorothioic acid trihydrate

The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C488" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C488" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000039741

S-2-(3-aminopropylamino)ethylphosphorothioic acid trihydrate

ethiofos

gammaphos

APAETP

Cytofos

Ethyol

YM-08310

2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate ester trihydrate

amifostine trihydrate

WR2721

WR-2721

WR 2721

S-(N-(3-aminopropyl)-2-aminoethyl)thiophosphoric acid trihydrate

aminopropylaminoethylthiophosphoric acid trihydrate

20537-88-6

http://purl.bioontology.org/ontology/PDQ/CDR0000042970

http://purl.bioontology.org/ontology/PDQ/CDR0000043453

http://purl.bioontology.org/ontology/PDQ/CDR0000043314

http://purl.bioontology.org/ontology/PDQ/CDR0000043479

http://purl.bioontology.org/ontology/PDQ/CDR0000042767

http://purl.bioontology.org/ontology/PDQ/CDR0000040857

http://purl.bioontology.org/ontology/PDQ/CDR0000041367

http://purl.bioontology.org/ontology/PDQ/CDR0000042708

http://purl.bioontology.org/ontology/PDQ/CDR0000042812

http://purl.bioontology.org/ontology/PDQ/CDR0000037934

http://purl.bioontology.org/ontology/PDQ/CDR0000042775

http://purl.bioontology.org/ontology/PDQ/CDR0000042989

http://purl.bioontology.org/ontology/PDQ/CDR0000043418

http://purl.bioontology.org/ontology/PDQ/CDR0000042902

http://purl.bioontology.org/ontology/PDQ/CDR0000042446

http://purl.bioontology.org/ontology/PDQ/CDR0000041054

http://purl.bioontology.org/ontology/PDQ/CDR0000041255

http://purl.bioontology.org/ontology/PDQ/CDR0000043015

http://purl.bioontology.org/ontology/PDQ/CDR0000043359

http://purl.bioontology.org/ontology/PDQ/CDR0000042778

http://purl.bioontology.org/ontology/PDQ/CDR0000043360

http://purl.bioontology.org/ontology/PDQ/CDR0000037858

http://purl.bioontology.org/ontology/PDQ/CDR0000040647

http://purl.bioontology.org/ontology/PDQ/CDR0000042871

http://purl.bioontology.org/ontology/PDQ/CDR0000041678

http://purl.bioontology.org/ontology/PDQ/CDR0000037838

http://purl.bioontology.org/ontology/PDQ/CDR0000043038

http://purl.bioontology.org/ontology/PDQ/CDR0000040651

http://purl.bioontology.org/ontology/PDQ/CDR0000038152

http://purl.bioontology.org/ontology/PDQ/CDR0000038405

http://purl.bioontology.org/ontology/PDQ/CDR0000043104

http://purl.bioontology.org/ontology/PDQ/CDR0000043321

http://purl.bioontology.org/ontology/PDQ/CDR0000041468

http://purl.bioontology.org/ontology/PDQ/CDR0000043153

http://purl.bioontology.org/ontology/PDQ/CDR0000042956

http://purl.bioontology.org/ontology/PDQ/CDR0000043033

http://purl.bioontology.org/ontology/PDQ/CDR0000043491

http://purl.bioontology.org/ontology/PDQ/CDR0000042827

http://purl.bioontology.org/ontology/PDQ/CDR0000039614

http://purl.bioontology.org/ontology/PDQ/CDR0000042925

http://purl.bioontology.org/ontology/PDQ/CDR0000041276

http://purl.bioontology.org/ontology/PDQ/CDR0000042811

C0591467

C2981204

C0729079

C4082393

C0729078

C4082394

C0015020

C1706792

2017-03-02

The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C488" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C488" NCI Thesaurus)

18318

2402

TRD

C488

CDR0000039741

296961

Drug/agent

amifostine

T109

T121